CDC: Artesunate Now First-Line Treatment for Severe Malaria in the United States

CDC is issuing new guidance to clinicians for the treatment of severe malaria cases in the United States (U.S.). This change in treatment protocol is necessary because the only FDA-approved intravenous (IV) antimalarial drug in the U.S., quinidine, has been discontinued by the manufacturer and will no longer be available. As of April 2019, artesunate, the WHO-recommended first-line treatment of severe malaria, will become the first-line treatment for severe malaria in the U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *